Clorox Company (CLX) Stock Falls on Q2 2026 Earnings

Clorox Company (CLX) reported second-quarter 2026 results with revenue of $1.67 billion (down 0.8% year‑over‑year) and diluted earnings per share of $1.29 (down 16.2% year‑over‑year).

Gross profit: $722 million (down 2.2% YoY)

Operating profit: $241 million (up 2.1% YoY)

Net income attributable to common shareholders: $159 million (up 8.2% YoY)

Cost of sales: $951 million (up 0.3% YoY)

Cash from operating activities: $311 million (up 72.8% YoY)

Purchases of property, plant and equipment: $42 million (down 20.8% YoY)

Cash and cash equivalents: $227 million (down 21.7% YoY)

Total liabilities: $5.58 billion (up 2.2% YoY)

On the estimates front, revenue came in slightly above the consensus estimate of $1.66 billion, while EPS missed the estimate of $1.45, representing roughly an 11% shortfall versus expectations.

Shares were down 2.37% since market close.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Clorox Company (The) Insider Trading Activity

Clorox Company (The) insiders have traded $CLX stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $CLX stock by insiders over the last 6 months:

ERIC H REYNOLDS (EVP - Chief Operating Officer) sold 15,041 shares for an estimated $1,861,847
PIERRE R BREBER purchased 4,000 shares for an estimated $416,516

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Clorox Company (The) Hedge Fund Activity

We have seen 433 institutional investors add shares of Clorox Company (The) stock to their portfolio, and 637 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MILLENNIUM MANAGEMENT LLC removed 1,380,694 shares (-92.3%) from their portfolio in Q3 2025, for an estimated $170,239,570
VAN ECK ASSOCIATES CORP added 1,312,471 shares (+93.9%) to their portfolio in Q3 2025, for an estimated $161,827,674
TWO SIGMA ADVISERS, LP added 1,310,100 shares (+180.8%) to their portfolio in Q3 2025, for an estimated $161,535,330
QUBE RESEARCH & TECHNOLOGIES LTD removed 1,263,303 shares (-53.6%) from their portfolio in Q3 2025, for an estimated $155,765,259
MAN GROUP PLC removed 903,818 shares (-79.7%) from their portfolio in Q3 2025, for an estimated $111,440,759
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 828,143 shares (+64.3%) to their portfolio in Q3 2025, for an estimated $102,110,031
INVESCO LTD. added 750,415 shares (+23.1%) to their portfolio in Q3 2025, for an estimated $92,526,169

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Clorox Company (The) Congressional Stock Trading

Members of Congress have traded $CLX stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $CLX stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 12/19 and 1 sale worth up to $15,000 on 11/12.
REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

Clorox Company (The) Analyst Ratings

Wall Street analysts have issued reports on $CLX in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Underweight" rating on 10/01/2025

To track analyst ratings and price targets for Clorox Company (The), check out Quiver Quantitative's $CLX forecast page.

Clorox Company (The) Price Targets

Multiple analysts have issued price targets for $CLX recently. We have seen 9 analysts offer price targets for $CLX in the last 6 months, with a median target of $114.0.

Here are some recent targets:

Chris Carey from Wells Fargo set a target price of $115.0 on 01/23/2026
Andrea Teixeira from JP Morgan set a target price of $114.0 on 01/16/2026
Peter Grom from UBS set a target price of $115.0 on 01/14/2026
Robert Moskow from TD Cowen set a target price of $108.0 on 01/08/2026
Bonnie Herzog from Goldman Sachs set a target price of $94.0 on 01/07/2026
Filippo Falorni from Citigroup set a target price of $109.0 on 12/17/2025
Dara Mohsenian from Morgan Stanley set a target price of $125.0 on 11/04/2025